Gastric & colorectal cancer Test result guide General information

When two tumor markers point in opposite directions — why CEA can fall while CA 19-9 rises, and reading the trend and imaging instead of a single number

2026.07.23 1 Views

Summary

During treatment two tumor markers can move in opposite directions. This explains why CEA may fall while CA 19-9 rises, and why doctors read the trend and imaging rather than a single value.

During cancer treatment, blood tests are used regularly to check tumor marker levels. Sometimes the report shows one marker dropping sharply, which brings relief, while another climbs, which brings worry. Feeling confused about whether treatment is 'working or not' when two numbers point in different directions is a completely natural reaction.

In colorectal cancer, two markers often followed together are CEA and CA 19-9. These tests measure the amount of certain proteins in the blood. They do not reveal the exact size or number of cancer sites; they are supporting indicators used to observe a trend over time. For this reason, the direction of change across several tests matters more than any single value.

There are real reasons why the two markers can move differently. CEA and CA 19-9 arise through somewhat different pathways, and CA 19-9 in particular can rise for reasons unrelated to cancer. It can go up when bile does not drain well and backs up (cholestasis), when the bile duct is compressed, with various changes in the liver, or with inflammation. Some people, because of their individual biology, barely produce CA 19-9 at all, so their level may stay low even when cancer is present.

Because of this, clinicians do not automatically read a rising marker as 'getting worse.' They weigh it alongside the trend of the other marker, the person's symptoms, and imaging (such as CT). For example, if one value clearly falls while only the other rises a little, the rising one may reflect a liver or bile issue, and a doctor may suggest, 'Let's not focus on that number this time; we'll continue a few more cycles and confirm with a CT scan.'

For patients and caregivers, it helps to record marker values by date. Rather than swinging with each single result, it is calming to ask which indicator your doctor is actually using to judge the response, and when the next imaging is scheduled. A marker is only one piece of the whole picture; on its own it does not decide the success or failure of treatment.

This article is for general information only and does not replace individual medical care. Because the interpretation of these numbers and the direction of treatment differ from person to person, please always discuss them with your own doctor.

Medical notice

This article is an anonymized, informational rewrite and translation of public posts from a patient community. It is not a medical diagnosis or treatment advice. Always consult your medical team about health decisions.

Gastric & colorectal cancer · Back to list

Gastric & colorectal cancer Hospital, insurance & practical

Moving Hospitals to Continue Chemotherapy and Being Told You Need the Pathology Block or Genetic Test Report — How Tumor Tissue Travels Between Hospitals and Why a New Hospital Wants to Recheck It

When you plan to continue chemotherapy at a different hospital from the one where you had surgery, this article explains what a pathology report, glass slide, and paraffin block each are and why a new hospital may need them, plus the loan-and-release process by which tissue moves between hospitals and the practical steps a patient can take.

2026.07.24 0 Views

Gastric & colorectal cancer Medical information

When You're Told 'There's No Change in Size' — Why Chemo Response in Peritoneal Stomach Cancer Isn't Measured by Size Alone, and Understanding Conversion Surgery and Intraperitoneal Chemo

In peritoneal stomach cancer, deposits are often 'non-measurable' on CT, so 'no change in size' doesn't automatically mean the chemo has failed. This piece explains how doctors judge response using ascites, symptoms, and tumor markers, and plainly describes switching lines of therapy, conversion surgery, and intraperitoneal chemotherapy.

2026.07.23 0 Views

Gastric & colorectal cancer Hospital, insurance & practical

Why hot packs and gloves end up on the first-chemo packing list — understanding oxaliplatin's acute cold sensitivity and what a caregiver can watch for during the infusion

Oxaliplatin, common in adjuvant chemo for stage III colon cancer, causes short-lived cold sensitivity for a few days after treatment, which is why hot packs and gloves help. It differs from chronic neuropathy; the article also covers infusion-reaction signs and a caregiver's role during the infusion.

2026.07.23 4 Views

Gastric & colorectal cancer Hospital, insurance & practical

When Your Surgeon Says "You'll See Medical Oncology From Now On" — Why Cancer Care Is Split Between Departments, and How to Keep Follow-Up Scans and Colonoscopy Going While You Decide About Chemotherapy

Explains why surgery and post-operative chemotherapy are typically handled by different departments, and why that transfer is a change of role rather than an end of care. Covers how to confirm which department orders CT scans and colonoscopy after a recurrence, how to request continued surveillance while still undecided about chemotherapy, and what details about a previously stopped chemotherapy course to bring to the new team.

2026.07.23 4 Views

Related

Moving Hospitals to Continue Chemotherapy and Being Told You Need the Pathology Block or Genetic Test Report — How Tumor Tissue Travels Between Hospitals and Why a New Hospital Wants to Recheck It

When You're Told 'There's No Change in Size' — Why Chemo Response in Peritoneal Stomach Cancer Isn't Measured by Size Alone, and Understanding Conversion Surgery and Intraperitoneal Chemo

Why hot packs and gloves end up on the first-chemo packing list — understanding oxaliplatin's acute cold sensitivity and what a caregiver can watch for during the infusion

When Your Surgeon Says "You'll See Medical Oncology From Now On" — Why Cancer Care Is Split Between Departments, and How to Keep Follow-Up Scans and Colonoscopy Going While You Decide About Chemotherapy